Fremont, CA – According to filings with the U.S. Securities and Exchange Commission, Aarvik Therapeutics is raising $8,333,333.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jagath Junutula played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aarvik Therapeutics
Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms. Aarvik Strategy to Improve the Therapeutic Index. Aarvik has developed a disruptive antibody engineering platform that creates function blocking antibodies, ADCs and other modalities. Stay tuned as we disclose more details about this revolutionary platform.

To learn more about Aarvik Therapeutics, visit http://www.aarviktx.com/

Contact:
Jagath Junutula, Chief Executive Officer
650-703-2498
jagath@aarviktx.com
https://www.linkedin.com/in/jagath/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved